Etanercept in Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic and progressive inflammatory disease primarily affecting the spine and sacroiliac (SI) joints. It leads to inflammatory back pain, stiffness, and, in severe cases, new bone formation such as syndesmophytes and ankylosis. The disease is categorized into two subsets: non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA. The condition imposes significant clinical and economic burdens on patients and healthcare systems, affecting employment, work productivity, leisure activities, mood, and interpersonal relationships.
Etanercept, a tumor necrosis factor inhibitor (TNFi), has proven effective in treating various forms of spondyloarthritis, including AS, psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA). This article provides a comprehensive review of etanercept’s efficacy, dosing strategies, impact on imaging progression, and its role in managing axSpA, based on a systematic review of published data from January 1, 2000, to April 1, 2021.
Mechanism of Action and Pharmacokinetics
Etanercept is a dimeric fusion protein composed of the extracellular domain of the human TNF receptor (TNFR2 or p75) linked to the crystallizable fragment (Fc) of human immunoglobulin G1 (IgG1). The Fc component includes the CH2 and CH3 domains and the hinge region but lacks the CH1 domain of IgG. This structure allows etanercept to mimic the function of soluble TNF receptors, competitively binding to TNF and inhibiting its interaction with transmembrane TNF receptors. Etanercept binds TNFα in a 1:1 stoichiometry, unlike monoclonal antibodies (mAbs) like adalimumab or infliximab, which can bind up to three molecules per TNFα trimer. Etanercept exhibits a 10- to 20-fold greater avidity for soluble TNFα compared to these mAbs.
Following subcutaneous injection, etanercept is slowly absorbed, reaching peak concentration in approximately 48 to 60 hours, and is cleared from the body with a half-life of 70 to 100 hours. It does not induce complement-dependent cytotoxicity as potently as infliximab or adalimumab due to the absence of the CH1 domain, which is crucial for C3 activation. Additionally, etanercept does not elicit neutralizing antidrug antibodies (ADAs), which are often associated with reduced therapeutic efficacy in other TNFis.
Clinical Applications and Dosing
Etanercept was one of the first TNFis approved by the European Medicines Agency in 2000 for treating autoimmune diseases beyond rheumatoid arthritis (RA), including plaque psoriasis, PsA, AS, nr-axSpA, and polyarticular juvenile idiopathic arthritis (JIA). However, its approval for nr-axSpA is limited in the United States, and in China, it is only indicated for RA and AS.
The recommended dosing for adults is 25 mg twice weekly or 50 mg once weekly for RA, PsA, AS, and nr-axSpA. For children over two years old, the dose is 0.4 mg/kg (up to 25 mg) twice weekly or 0.8 mg/kg (up to 50 mg) once weekly. The American College of Rheumatology (ACR) recommends continuing etanercept at the regular dose during the first and second trimesters of pregnancy, with discontinuation in the third trimester if the disease is well-controlled. Etanercept is also considered compatible with breastfeeding. No dose adjustments are required for patients with renal or hepatic impairments.
Efficacy in Axial Spondyloarthritis
Both short-term randomized controlled trials (RCTs) and long-term studies have demonstrated etanercept’s efficacy in treating axSpA. A head-to-head comparison of etanercept and adalimumab in AS patients showed that both drugs significantly improved disease activity over 16 weeks, with comparable efficacy and safety profiles. The 10-year results of the ESTHER trial revealed sustained clinical response in patients with early axSpA, with mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) scores consistently below 2, and mean Ankylosing Spondylitis Disease Activity Score (ASDAS) below 2.1.
Timing of Treatment and Dose Reduction
Early intervention with etanercept, particularly targeting bone marrow edema lesions detected by magnetic resonance imaging (MRI), is crucial before the onset of fat transformation. However, etanercept is not effective in patients with suspected nr-axSpA who have high disease activity but lack positive findings on SI joint MRI or elevated C-reactive protein levels.
Dose reduction strategies have been explored in patients achieving remission. A study in Italy randomized patients to receive 50 mg weekly or 50 mg every other week. At follow-up, 86.3% of patients in the weekly group and 90.4% in the biweekly group remained in remission, indicating that dose reduction is feasible without compromising efficacy. A retrospective study from China suggested that tapering the etanercept dose by 25% every three months after achieving remission for over 12 months can reduce relapse rates and improve cost-effectiveness.
Impact on Imaging Progression
Etanercept has shown promise in decelerating structural damage in the SI joints. The ESTHER trial reported minimal changes in the sacroiliitis sum score over six years, with mean changes of 0.13, 0.27, and 0.09 in the intervals from baseline to year 2, year 2 to year 4, and year 4 to year 6, respectively. The EMBARK trial, a 12-week RCT in nr-axSpA patients, demonstrated significant reductions in erosions and increased backfill in the SI joints with etanercept compared to placebo. Continued improvements in SPARCC MRI scores were observed up to 104 weeks.
Etanercept also appears to slow radiographic progression in the spine, a key concern in axSpA. Longitudinal analyses from the Alberta prospective cohort indicated that TNFis, including etanercept, reduce spinal radiographic progression in AS patients.
Safety Profile
While etanercept is generally well-tolerated, it carries risks of serious infections, malignancies, and lymphoproliferative disorders. However, studies comparing etanercept with monoclonal TNFis in RA and other autoimmune diseases suggest a lower risk of severe infections, tuberculosis, and lymphoma with etanercept. The immunogenicity of etanercept is also lower, with no reported cases of ADAs in patients experiencing secondary treatment failure.
Cost-Effectiveness and Accessibility
Etanercept is covered by Chinese medical insurance, with reimbursement rates as high as 80% in some cities like Beijing. Its favorable cost-performance ratio makes it a promising option for the long-term management of axSpA.
In conclusion, etanercept is a highly effective TNFi for treating axSpA, with a well-established safety profile and lower immunogenicity compared to other TNFis. Its ability to decelerate structural damage, combined with feasible dose reduction strategies, makes it a valuable therapeutic option. Continued research and clinical experience will further refine its use in managing this challenging condition.
doi.org/10.1097/CM9.0000000000001986
Was this helpful?
0 / 0